Treatment of pulmonary hypertension

The Lancet Respiratory Medicine

Volumn 4, Issue 4, 2016, Pages 323-336

  Hoeper, Marius M ^a   McLaughlin, Vallerie V ^b   Dalaan, Abdullah M Al ^c   Satoh, Toru ^d   Galiè, Nazzareno ^e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; MACITENTAN; PROSTACYCLIN; RIOCIGUAT; SELEXIPAG; SILDENAFIL; TADALAFIL; ANTIHYPERTENSIVE AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; GUANYLATE CYCLASE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN RECEPTOR; VASODILATOR AGENT;

BLOOD VESSEL REACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; HUMAN; INTERSTITIAL LUNG DISEASE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MOLECULARLY TARGETED THERAPY; OXYGEN THERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; AGONISTS; COMPLICATION; DISEASE FREE SURVIVAL; LUNG DISEASE;

ANTIHYPERTENSIVE AGENTS; DISEASE-FREE SURVIVAL; ENDOTHELIN RECEPTOR ANTAGONISTS; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES; PHOSPHODIESTERASE 5 INHIBITORS; PROSTAGLANDINS I; RECEPTORS, EPOPROSTENOL; SOLUBLE GUANYLYL CYCLASE; VASODILATOR AGENTS;

EID: 84960362801     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00542-1     Document Type: Review

References (107)

1. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013, 62(suppl):D42-D50.
2. Tuder RM, Archer SL, Dorfmüller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013, 62(suppl):D4-12.
3. Vonk-Noordegraaf A, Haddad F, Chin KM, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol 2013, 62(suppl):D22-D33.
4. Vachiéry JL, Adir Y, Barberà JA, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 2013, 62(suppl):D100-D108.
5. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013, 62(suppl):D34-D41.
6. Galiè N, Humbert M, Vachiery JL, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016, 37:67-119.
7. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015, 46:903-975.
8. Hoeper Marius M, Humbert Marc, Souza Rogerio, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016, published online March 11. http://dx.doi.org/10.1016/S2213-2600(15)00543-3.
9. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013, 62(suppl):D60-D72.
10. Kim NH, Delcroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013, 62(suppl):D92-D99.
11. Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 2014, 130:2189-2208.
12. McLaughlin VV, Shah SJ, Souza R, Humbert M Management of pulmonary arterial hypertension. J Am Coll Cardiol 2015, 65:1976-1997.
13. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
14. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012, 142:448-456.
15. Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 2012, 39:945-955.
16. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004, 170:1212-1217.
17. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006, 114:48-54. the Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators.
18. Rhodes CJ, Wharton J, Howard L, Gibbs JS, Vonk-Noordegraaf A, Wilkins MR Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. Eur Respir J 2011, 38:1453-1460.
19. Wagenvoort CA The pathology of primary pulmonary hypertension. Circulation 1970, 101:1163-1184.
20. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984, 70:580-587.
21. Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014, 129:57-65.
22. Preston IR, Roberts KE, Miller DP, et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term pah disease management (REVEAL). Circulation 2015, 132:2403-2411.
23. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995, 151:384-389.
24. Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010, 31:1898-1907.
25. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
26. Galiè N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008, 371:2093-2100.
27. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117:3010-3019. the Ambrisentan in Pulmonary Arterial Hypertension, RandomizedRandomized, Double-BlindDouble-Blind, Placebo-ControlledPlacebo-Controlled, MulticenterMulticenter, Efficacy Studies (ARIES) GroupEfficacy Studies (ARIES) Group.
28. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157. the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group.
29. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149:521-530.
30. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903. the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group.
31. Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013, 369:330-340. the PATENT-1 Study Group.
32. Galiè N, Müller K, Scalise AV, Grünig E PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J 2015, 45:1314-1322.
33. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996, 334:296-301. the Primary Pulmonary Hypertension Study Group.
34. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329. the Aerosolized Iloprost Randomized Study Group.
35. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174:1257-1263.
36. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006, 28:691-694.
37. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012, 142:1383-1390.
38. Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 2013, 144:952-958. the FREEDOM-C2 Study Team.
39. Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013, 127:624-633.
40. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010, 55:1915-1922.
41. McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015, 46:405-413.
42. Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015, 373:834-844. the AMBITION Investigators.
43. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013, 369:809-818. the SERAPHIN Investigators.
44. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015, 373:2522-2533. the GRIPHON Investigators.
45. Burgess G, Hoogkamer H, Collings L, Dingemanse J Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008, 64:43-50.
46. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005, 60:107-112.
47. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30:2493-2537. the ESC Committee for Practice Guidelines (CPG).
48. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association. Circulation 2009, 119:2250-2294. the ACCF/AHA.
49. McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol 2013, 62(suppl):D73-D81.
50. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012, 39:589-596.
51. Dardi F, Manes A, Palazzini M, et al. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J 2015, 46:414-421.
52. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010, 137:376-387.
53. Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013, 168:871-880.
54. Sitbon O, Jaïs X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014, 43:1691-1697.
55. Kemp K, Savale L, O'Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant 2012, 31:150-158.
56. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004, 24:353-359.
57. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014-an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015, 34:1-15.
58. Miller WL, Grill DE, Borlaug BA Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail 2013, 1:290-299.
59. Gerges C, Gerges M, Lang MB, et al. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. Chest 2013, 143:758-766.
60. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997, 134:44-54.
61. Packer M, McMurray J, Massie BM, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005, 11:12-20.
62. Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364:347-354. the EARTH investigators.
63. Lüscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002, 106:2666-2672. the Heart Failure ET(A) Receptor Blockade Trial.
64. Kalra PR, Moon JC, Coats AJ Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?. Int J Cardiol 2002, 85:195-197.
65. Kaluski E, Cotter G, Leitman M, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension-a multi-center randomized study. Cardiology 2008, 109:273-280.
66. Alaeddini J, Uber PA, Park MH, Scott RL, Ventura HO, Mehra MR Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 2004, 94:1475-1477.
67. Guazzi M, Vicenzi M, Arena R, Guazzi MD PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011, 4:8-17.
68. Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005, 127:1647-1653.
69. Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007, 115:59-66.
70. Salloum FN, Abbate A, Das A, et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 2008, 294:H1398-H1406.
71. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11:214-222.
72. Guazzi M, Vicenzi M, Arena R, Guazzi MD Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011, 124:164-174.
73. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013, 309:1268-1277. the RELAX Trial.
74. Hoendermis ES, Liu LC, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015, 36:2565-2573.
75. Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013, 128:502-511. the Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT) Study Group.
76. Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest 2014, 146:1274-1285.
77. Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED Randomized Trial. JAMA 2015, 314:2251-2262. the SOCRATES-REDUCED Investigators and Coordinators.
78. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991, 325:1468-1475. the PROMISE Study Research Group.
79. Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013, 62(suppl):D109-D116.
80. Behr J, Ryu JH Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008, 31:1357-1367.
81. Chaouat A, Naeije R, Weitzenblum E Pulmonary hypertension in COPD. Eur Respir J 2008, 32:1371-1385.
82. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008, 32:619-628.
83. Lederer DJ, Bartels MN, Schluger NW, et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD 2012, 9:268-275.
84. Rietema H, Holverda S, Bogaard HJ, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008, 31:759-764.
85. Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010, 181:270-278.
86. Blanco I, Santos S, Gea J, et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J 2013, 42:982-992.
87. Goudie AR, Lipworth BJ, Hopkinson PJ, Wei L, Struthers AD Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2014, 2:293-300.
88. King TE, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 177:75-81.
89. King TE, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184:92-99.
90. Seibold JR, Denton CP, Furst DE, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010, 62:2101-2108.
91. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013, 158:641-649. the ARTEMIS-IPF Investigators.
92. Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 2013, 42:1622-1632. the MUSIC Study Group.
93. Corte TJ, Keir GJ, Dimopoulos K, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2014, 190:208-217. the BPHIT Study Group.
94. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010, 363:620-628. the Idiopathic Pulmonary Fibrosis Clinical Research Network.
95. Hoeper MM, Halank M, Wilkens H, et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J 2013, 41:853-860.
96. Hoeper MM, Madani MM, Nakanishi N, Meyer B, Cebotari S, Rubin LJ Chronic thromboembolic pulmonary hypertension. Lancet Respir Med 2014, 2:573-582.
97. Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients. Ann Thorac Surg 2012, 94:97-103.
98. Kataoka M, Inami T, Hayashida K, et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012, 5:756-762.
99. Fukui S, Ogo T, Morita Y, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J 2014, 43:1394-1402.
100. Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013, 369:319-329. the CHEST-1 Study Group.
101. Spiekerkoetter E, Sung YK, Sudheendra D, et al. Low-dose FK506 (Tacrolimus) in end-stage pulmonary arterial hypertension. Am J Respir Crit Care Med 2015, 192:254-257.
102. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010, 182:1171-1177.
103. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013, 127:1128-1138.
104. Frost AE, Barst RJ, Hoeper MM, et al. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant 2015, 34:1366-1375.
105. Speich R, Ulrich S, Domenighetti G, et al. Efficacy and safety of long-term imatinib therapy for pulmonary arterial hypertension. Respiration 2015, 89:515-524.
106. Chen SL, Zhang H, Xie DJ, et al. Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the pulmonary artery denervation-1 study. Circ Cardiovasc Interv 2015, 8. pii: e002837.
107. Chen SL, Zhang FF, Xu J, et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol 2013, 62:1092-1100.